Hsbc Holdings PLC Boosts Stock Position in Hims & Hers Health, Inc. $HIMS

Hsbc Holdings PLC increased its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 150.6% during the first quarter, HoldingsChannel.com reports. The firm owned 84,159 shares of the company’s stock after acquiring an additional 50,577 shares during the quarter. Hsbc Holdings PLC’s holdings in Hims & Hers Health were worth $1,741,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. SG Americas Securities LLC grew its holdings in shares of Hims & Hers Health by 25.6% during the fourth quarter. SG Americas Securities LLC now owns 371,553 shares of the company’s stock valued at $12,064,000 after buying an additional 75,679 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Hims & Hers Health by 7.2% during the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after acquiring an additional 1,407,651 shares in the last quarter. Munich Reinsurance Co Stock Corp in Munich bought a new position in Hims & Hers Health in the 4th quarter valued at approximately $11,187,000. Cunning Capital Partners LP purchased a new stake in Hims & Hers Health during the 4th quarter valued at $1,110,000. Finally, Virtu Financial LLC purchased a new stake in Hims & Hers Health during the 4th quarter valued at $1,937,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: The FDA panel’s favorable peptide recommendation could eventually broaden Hims & Hers’ addressable market and support its emerging peptide therapy business. FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight
• Neutral Sentiment: Truist raised its price target on HIMS to $27 from $23, but kept a hold rating, suggesting the firm sees limited upside from current levels. Tickerreport.com
• Neutral Sentiment: Recent commentary and search interest have kept HIMS in focus, reflecting elevated trading attention around the FDA-driven peptide story. Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
• Negative Sentiment: The sharp pullback appears consistent with a sell-the-news move as traders locked in gains after the initial FDA-related spike, since the regulatory process is not finished. Why Is HIMS Stock Rallying 13% Today?
• Negative Sentiment: Insider selling and mixed hedge fund positioning may also weigh on investor sentiment, as many major holders reduced exposure in the latest quarter. Hims & Hers Health Slides as Traders Fade Peptide Rally

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, Director David B. Wells purchased 48,400 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were acquired at an average price of $24.23 per share, for a total transaction of $1,172,732.00. Following the purchase, the director directly owned 224,417 shares of the company’s stock, valued at $5,437,623.91. The trade was a 27.50% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Oluyemi Okupe sold 18,197 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $34.03, for a total transaction of $619,243.91. Following the sale, the chief financial officer directly owned 284,321 shares of the company’s stock, valued at approximately $9,675,443.63. The trade was a 6.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 83,126 shares of company stock worth $2,711,339. 11.76% of the stock is currently owned by corporate insiders.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $28.10 on Monday. The firm has a market capitalization of $6.50 billion, a P/E ratio of -312.26, a PEG ratio of 79.05 and a beta of 2.35. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43. The business has a fifty day moving average of $30.75 and a 200 day moving average of $26.28.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The firm had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm’s revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.20 EPS. As a group, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.03 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on HIMS shares. UBS Group set a $23.00 price target on Hims & Hers Health in a report on Friday, May 22nd. JPMorgan Chase & Co. decreased their target price on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Truist Financial upped their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Friday. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $25.00 price target on shares of Hims & Hers Health in a report on Tuesday, May 5th. Finally, Wall Street Zen lowered shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Four research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Hims & Hers Health has an average rating of “Hold” and an average target price of $31.43.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.